We therefore envisage that reducing neuronal hyperexcitability by inhibiting the interaction between Pde6δ and Rap1 has therapeutic potential not only in AD, but also seizure disorders such as epilepsy. The gene discussed is PDE6D; the disease is Alzheimer disease.